Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer

被引：0
|
作者：
Kawahara, Hidejiro [1 ]
Yanaga, Katsuhiko [1 ]
机构：
[1] Jikei Univ, Sch Med, Dept Surg, Tokyo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1448
引用
收藏
页码：601 / 601
页数：1
相关论文
共 50 条
  • [1] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    [J]. ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [2] The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
    Kosugi, Chihiro
    Kamiyama, Hirohiko
    Yoshida, Yoichiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Fukazawa, Atsuko
    Matsuda, Akihisa
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Narushima, Kazuo
    Shuto, Kiyohiko
    Sakamoto, Kazuhiro
    Koda, Keiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoichiro Yoshida
    Takeshi Yamada
    Hirohiko Kamiyama
    Chihiro Kosugi
    Keiichiro Ishibashi
    Hiroshi Yoshida
    Hideyuki Ishida
    Satoru Yamaguchi
    Hidekazu Kuramochi
    Atsuko Fukazawa
    Hiromichi Sonoda
    Kazuhiko Yoshimatsu
    Akihisa Matsuda
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Koda
    [J]. International Journal of Clinical Oncology, 2021, 26 : 111 - 117
  • [4] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [5] The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
    Kamiyama, H.
    Yoshida, Y.
    Yoshida, H.
    Kosugi, C.
    Ishibashi, K.
    Ihara, K.
    Takahashi, M.
    Kuramochi, H.
    Fukazawa, A.
    Sonoda, H.
    Yoshimatsu, K.
    Matsuda, A.
    Yamaguchi, S.
    Ishida, H.
    Hasegawa, S.
    Yamada, T.
    Sakamoto, K.
    Koda, K.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 157 - 157
  • [6] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [7] Biweekly TAS-102 and bevacizumab as a third-line chemotherapy for metastatic colorectal cancer: A phase II multicenter clinical trial (TAS-CC4 study)
    Yoshida, Y.
    Yamada, T.
    Matsuoka, H.
    Hirata, K.
    Kuramochi, H.
    Kosugi, C.
    Takahashi, M.
    Fukazawa, A.
    Sonoda, H.
    Matsuda, A.
    Watanabe, T.
    Koizumi, M.
    Aisu, N.
    Hasegawa, S.
    Yoshida, H.
    Sakamoto, K.
    Ishida, H.
    Koda, K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 235 - 235
  • [8] Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
    Li, Qizheng
    Zhang, Xia
    Fan, Buqun
    Yang, Yudie
    Cui, Xiaonan
    Zhang, Jie
    Jiang, Kaiteng
    Zhang, Chunxia
    Zhang, Bin
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] TAS-102 for metastatic refractory colorectal cancer
    Cleghorn, Sean
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [10] TAS-102 for the treatment of metastatic colorectal cancer
    Salvatore, Lisa
    Rossini, Daniele
    Moretto, Roberto
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Loupakis, Fotios
    Falcone, Alfredo
    Masi, Gianluca
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1283 - 1292
12345